Midazolam maleate
Buccolam, Midazolam, Midozalam, Nayzilam, Seizalam (midazolam maleate) is a small molecule pharmaceutical. Midazolam maleate was first approved as Versed on 1985-12-20. It is used to treat anxiety disorders, psychomotor agitation, and status epilepticus in the USA. It has been approved in Europe to treat epilepsy.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| versed daily sunscreen spf 50 | C200263 | 2025-12-22 |
| versed guards up daily mineral sunscreen broad spectrum spf 35 | OTC monograph final | 2022-08-30 |
| versed multi serum skin tint spf 40 | C200263 | 2025-12-22 |
| versed multi serum skin tint spf 40 deep cool | C200263 | 2025-12-22 |
| versed multi serum skin tint spf 40 deep neutral | C200263 | 2025-12-22 |
| versed multi serum skin tint spf 40 deep wrm | C200263 | 2025-12-22 |
| versed multi serum skin tint spf 40 light medium neutral | C200263 | 2025-12-22 |
| versed multi serum skin tint spf 40 light medium olive | C200263 | 2025-12-22 |
| versed multi serum skin tint spf 40 light neutral | C200263 | 2025-12-22 |
| versed multi serum skin tint spf 40 light peach | C200263 | 2025-12-22 |
Show 7 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MIDAZOLAM, NAYZILAM, UCB INC | |||
| 2026-05-17 | ODE-243 | ||
MIDAZOLAM HYDROCHLORIDE, SEIZALAM, MMT | |||
| 2025-09-14 | ODE-207 | ||
HCPCS
No data
Clinical
Clinical Trials
1661 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft rejection | D006084 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 3 | — | — | — | — | 3 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 3 | — | — | — | — | 3 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Hepatitis c | D006526 | — | B19.2 | 2 | — | — | — | — | 2 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Midazolam maleate |
| INN | midazolam |
| Description | Midazolam is an imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively. It has a role as a GABAA receptor agonist, an anticonvulsant, an anxiolytic drug, an apoptosis inducer, an antineoplastic agent, a muscle relaxant, a sedative, a general anaesthetic and a central nervous system depressant. It is an organochlorine compound, an imidazobenzodiazepine and a member of monofluorobenzenes. |
| Classification | Small molecule |
| Drug class | Benzodiazepine |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2.O=C(O)/C=C\C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 59467-70-8 |
| RxCUI | 6960 |
| ChEMBL ID | CHEMBL2106922 |
| ChEBI ID | — |
| PubChem CID | 4192 |
| DrugBank | DB00683 |
| UNII ID | R60L0SM5BC (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,080 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,248 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use